NeoDynamics – Management elaborates on options for long-term financing
Meet CEO Anna Eriksrud and CFO Aaron Wong who will elaborate on options to raise long-term capital to enable the commercialization of NeoNavia in the US. The event takes place Wednesday the 15th of March 2.00 PM.
The Board of Directors and Management of NeoDynamics are currently exploring various options to raise long-term capital to enable the commercialization and execution of the Company’s US strategy, following the FDA clearance received in September 2022 for NeoDynamic’s innovative pulse biopsy system NeoNavia®. Funding proceeds will also be used to support the Company’s continued expansion and operations in Europe. These options for raising long-term capital include debt financing, a potential dual stock exchange listing to expand the Company’s shareholder base, as well as issues of new shares, warrants and/or convertible instruments.
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in the USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 10.46 AM 10 March 2023.
